Transcranial Photobiomodulation for Reducing Autism Symptoms in Children
NCT: NCT04660552 · COMPLETED
Brief Summary
The hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 6, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experimental condition twice a week for 8 weeks. Results will be measured through parental interviews, standardized CARS2 (Childhood Autism Rating Scales, 2nd Edition) and data collected from EEG.
Frequently Asked Questions
What is Transcranial Photobiomodulation for Reducing Autism Symptoms in Children?
Transcranial Photobiomodulation for Reducing Autism Symptoms in Children is a clinical trial registered under NCT04660552. Current status: COMPLETED.
What is the status of NCT04660552?
The current status of NCT04660552 (Transcranial Photobiomodulation for Reducing Autism Symptoms in Children) is: COMPLETED.
When did Transcranial Photobiomodulation for Reducing Autism Symptoms in Children start?
Transcranial Photobiomodulation for Reducing Autism Symptoms in Children started on 2020-11-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.